title: Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases.
abstract: BACKGROUND
  Only 5-10% of colorectal cancer patients (pts) with liver metastases are eligible for surgical resection. Regional and systemic chemotherapy represents the best therapeutic options for unresectable metastases.
  
  
  METHODS
  In a randomized phase II trial 123 pts were enrolled with a minimum follow-up of 3 years. In Arm A 58 pts were submitted to intraarterial continuous infusion of cisplatin (CDDP), 24 mg/m2/day, while the other 65 were included in Arm B (bolus of CDDP, 24 mg/m2/day). All the pts were also given i.v. escalating doses of fluorouracil. Response was evaluated after a minimum of 3 cycles.
  
  
  RESULTS
  Toxicity > or = G3 was lower in Arm B. The objective response rate was 52% in all the series, the complete responses being 17.3% (17.6% vs. 17% in Arms A and B, respectively). The overall median survival was 18 months rising to 28 months in the responders.
  
  
  CONCLUSIONS
  CDDP HAI provided similar results as FUdR in terms of response to treatment. Moreover, long-term survivors were unexpectedly observed.
authors.affiliation: Department of Surgical Oncology, Regina Elena Cancer Institute, Via Elio Chianesi, 53, 00013 Rome, Italy.
authors.forename: Raffaello
authors.initials: R
authors.lastname: Mancini
authors.forename: Manfredo
authors.initials: M
authors.lastname: Tedesco
authors.forename: Carlo
authors.initials: C
authors.lastname: Garufi
authors.forename: Angelo
authors.initials: A
authors.lastname: Filippini
authors.forename: Stefano
authors.initials: S
authors.lastname: Arcieri
authors.forename: Mauro
authors.initials: M
authors.lastname: Caterino
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pizzi
authors.forename: Enrico
authors.initials: E
authors.lastname: Cortesi
authors.forename: Antonella
authors.initials: A
authors.lastname: Spila
authors.forename: Isabella
authors.initials: I
authors.lastname: Sperduti
authors.forename: Maurizio
authors.initials: M
authors.lastname: Cosimelli
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002404:Catheterization; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006499:Hepatic Artery; D006801:Humans; D015918:Infusion Pumps, Implantable / Q000009:adverse effects; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery
chemical_list: D002945:Cisplatin; D005472:Fluorouracil